Crackdown On Anti-Cancer Drugs Making Unit For Not Following Norms

Hyderabad: A drug manufacturing unit involved in production of anti-cancer injections as well as antibiotics without following the prescribed norms — was busted by the officials of Drugs Control Administration (DCA) on Wednesday.

The production unit was found making anti-cancer drug cyclophosphamide injection illegally during the raid conducted on Indian Genomix Pvt. Ltd at Cherlapally.

The company was involved in manufacturing cytotoxic, anti-cancer drugs as well as antibiotic injections. Without following the good manufacturing practices (GMPs) guidelines, these two types of drugs were being made at the same facility posing a major risk of cross-contamination of medicines. The production unit was not following the norms and thereby posing a serious health risk, DCA DG V.B. Kamalasan Reddy stated in a press statement on Wednesday.

The cytotoxic anti-cancer drug ‘cyclophosphamide injection’ alters the genetic material (DNA and RNA) of the cells and hence checks the growth or replication of cancer cells. It is used in providing chemotherapy to cancer patients and can cause severe side-effects, Kamalasan Reddy added.

The cytotoxic anti-cancer drugs should be manufactured at a separate, dedicated and self-contained production facility and as per the good manufacturing practices (GMPs) guidelines, so as to ensure a clear-cut separation of cytotoxic substances from other general drugs; otherwise ‘cross-contamination’ of general drugs with ‘cytotoxic anti-cancer drugs’ might lead to serious health consequences in a patient who is not suffering from cancer, he said.

A dedicated facility for handling cytotoxic drugs is crucial and Indian Genomix Pvt. Ltd. located at IDA Cherlapally was not following the norms while producing the anti-cancer drug. The drug manufacturing unit did have the requisite license for making anti-cancer drugs. The company was involved in manufacturing antibiotic injections, together with anti-cancer drugs posing a serious medical hazard, said the DG.

Related Posts

‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

New Delhi: A pharma group has sought extension for those production units that have already submitted upgradation plans and can demonstrate execution progress, even as the drug regulatory authority seems…

Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

New Delhi: Improving access to new age medicines for obesity and diabetes over the next few years would be a key enabler for the growth of the domestic pharmaceutical industry,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

National Pharmaceutical Pricing Authority fixes retail price of 37 new drugs

National Pharmaceutical Pricing Authority fixes retail price of 37 new drugs

Massive Drug Bust in Bijnor: CBN Seizes Over 6.5 Lakh Tablets

Massive Drug Bust in Bijnor: CBN Seizes Over 6.5 Lakh Tablets

Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

Strides Pharma Science arm New York facility gets 4 USFDA observations

Strides Pharma Science arm New York facility gets 4 USFDA observations